



GOOD PEOPLE  
*for* GOOD HEALTH

June 30, 2022

**BSE Ltd.**

Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai 400 001

**BSE Scrip Code : 506943**

**Stock Symbol: JBCHEPHARM**

**Sub: Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Dear Sir/Madam,

In compliance with Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to submit that the Board of Directors of J.B. Chemicals & Pharmaceuticals Limited (**JB Pharma**) at its meeting held on June 29, 2022 has considered and approved the acquisition of portfolio of brands, for use and exploitation within India, from Dr Reddy's Laboratories Limited.

Enclosed as Annexure-I is the information pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 with respect to this acquisition.

We request you to take the above information on record.

Thanking you,

Yours faithfully,

For J. B. Chemicals & Pharmaceuticals Ltd.

**Sandeep Phadnis**  
**Vice President- Secretarial**  
**& Company Secretary**

**Registered Office:**

J.B. Chemicals & Pharmaceuticals Limited,  
CIN: L24390MH1976PLC019380  
Neelam Centre, 'B' Wing, 4<sup>th</sup> Floor, Hind Cycle Road,  
Worli, Mumbai – 400030, T:+91 22 24822222

**Corporate Office:**

J.B. Chemicals & Pharmaceuticals Limited,  
CIN: L24390MH1976PLC019380  
Cnergy IT Park, Unit A, 8<sup>th</sup> Floor, Appa Saheb Marathe Marg,  
Prabhadevi, Mumbai – 400025, T:+91 22 24395200/5500

[www.jbpharma.com](http://www.jbpharma.com)



GOOD PEOPLE  
for GOOD HEALTH

ANNEXURE - I

Disclosure of information pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

S. No.	Particulars	Disclosure
1.	Name of the target entity from whom the assets are taken over, details in brief such as size, turnover etc.	<b>Dr Reddy's Laboratories Limited</b>  JB Chemicals & Pharmaceuticals limited ( JB Pharma) entered into an agreement with Dr. Reddy's Laboratories Ltd. to acquire four of its brands "Z&D", "Pedicloryl", "Pecef" and "Ezinapi" for the India market  All four brands are focused on the paediatric segment in the country with a total covered market size of 1800 crores as per IQVIA data. The combined sales of these brands as per internal estimates was INR ~33 crores for FY 2021-22
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arms length";	No
3.	Industry to which the entity being acquired belongs	Pharmaceuticals

Registered Office:

J.B. Chemicals & Pharmaceuticals Limited,  
CIN: L24390MH1976PLC019380  
Neelam Centre, 'B' Wing, 4<sup>th</sup> Floor, Hind Cycle Road,  
Worli, Mumbai – 400030, T:+91 22 24822222

Corporate Office:

J.B. Chemicals & Pharmaceuticals Limited,  
CIN: L24390MH1976PLC019380  
Cnergy IT Park, Unit A, 8<sup>th</sup> Floor, Appa Saheb Marathe Marg,  
Prabhadevi, Mumbai – 400025, T:+91 22 24395200/5500



GOOD PEOPLE  
for GOOD HEALTH

4.	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	JB Pharma sees good growth potential from the acquired brands as they are synergistic with its paediatric segment and will help it significantly leverage its field force strength
5.	Brief details of any governmental or regulatory approvals required for the acquisition	No government/ regulatory approvals are required
6.	Indicative time period for completion of the acquisition	The Acquisition shall be completed within next few working days
7.	Nature of consideration - whether cash consideration or share swap and details of the same;	Cash. The acquisition shall be funded primarily through long term debt.
8.	Cost of acquisition or the price at which the shares are acquired	<b>INR ~98.3 Crores (excluding working capital and taxes)</b>
9.	Percentage of shareholding / control acquired and / or number of shares acquired	Not applicable
10.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	JB Chemicals & Pharmaceuticals limited ( JB Pharma) entered into an agreement with Dr. Reddy's Laboratories Ltd. to acquire four of its brands in paediatric segment "Z&D", "Pedicloryl", "Pecef" and "Ezinapi" for the India market. Internal sales estimates for FY 21-22 was INR ~33 crores for the combined brands Internal sales estimates for FY 20-21 was INR ~25 crores Internal sales estimates for FY 19-20 was INR ~40 crores.

**Registered Office:**

J.B. Chemicals & Pharmaceuticals Limited,  
CIN: L24390MH1976PLC019380  
Neelam Centre, 'B' Wing, 4<sup>th</sup> Floor, Hind Cycle Road,  
Worli, Mumbai – 400030, T:+91 22 24822222

**Corporate Office:**

J.B. Chemicals & Pharmaceuticals Limited,  
CIN: L24390MH1976PLC019380  
Energy IT Park, Unit A, 8<sup>th</sup> Floor, Appa Saheb Marathe Marg,  
Prabhadevi, Mumbai – 400025, T:+91 22 24395200/5500